Shots: Ci:z’s acquisition holds two-third of its shares for $52.3/share and ~$2041M as total deal value along with its dermatology products i.e. Dr.Ci:Labo, Labo Labo and Genomer The transaction is expected to enhance and strengthen J&J’s footprints in Japan with its effective dermatology products On 29 Oct, 2018 J&J will announce its tender offer (acquisition […]Read More
Tags : Dermatology Portfolio
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US